INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) is an important therapy for a number of malignant and non-malignant diseases. The broader application of allo-SCT is limited by several complications including the development of graft versus host disease (GVHD) and pulmonary toxicity. Diffuse lung injury can occur in 25-55% of allo-SCT recipients [1] [2] [3] [4] [5] [6] . In approximately 50% of patients, infectious organisms are not identified and these cases have been defined as idiopathic pneumonia syndrome (IPS). IPS is associated with mortality rates of greater than 70% despite the use of high dose steroids, broad-spectrum anti-microbial agents and aggressive supportive measures 1, 4 . This form of lung injury is characterized by complex pathophysiology involving cytotoxicity from irradiation and chemotherapy 7, 8 , the production of inflammatory cytokines [9] [10] [11] [12] [13] [14] and the recruitment of both donor T cells and accessory cells 12, [15] [16] [17] .
The expression of several chemokines is also increased in the lung after allogeneic SCT [18] [19] [20] [21] , and recent data from our group have shown mechanistic links between specific chemokine receptor:ligand interactions and the recruitment of donor T cells, monocytes and macrophages to the lung during IPS 19, 21 . Regulated on activation, normal T cell expressed and secreted (RANTES / CCL5) is a member of the CC chemokine family of proteins that is strongly chemoattractant for activated T cells, monocytes, eosinophils and basophils 22, 23 . Increased RANTES expression has been shown in a number of experimental systems including those modeling transplantation rejection 24 , sclerodermatous GVHD 25 and acute lung injury after allo-SCT [18] [19] [20] . RANTES can be produced by several cell types including fibroblasts 26 , epithelial [27] [28] [29] and endothelial cells 30, 31 , activated T cells 32 , and macrophages 33 , and its expression can be induced by proinflammatory cytokines including TNFK, IL-1L and IFNM 20, [26] [27] [28] [29] 31 . CCR1 and CCR5 are the primary receptors for RANTES. These receptors are expressed on a variety of cells We used a well-established murine SCT model wherein IPS develops following myeloablative conditioning and in the context of major and minor histocompatibility differences between donor and recipient to study the role of RANTES of leukocyte infiltration into the lung. IPS in this system is dependent upon the infusion of allogeneic T cells along with the pretransplant radiation dose 35 and involves the recruitment of alloreactive CD4+ and CD8+ T cells to the lung 19, 20, 35 .
Although the severity of IPS is exacerbated by the addition of cytoxan to total body irradiation (TBI) in a related SCT model 16 the effects of "chemotherapy only" conditioning regimens on the development of IPS have yet to be explored in this system. Importantly, lung injury that develops in this model is defined by several features that characterize human disease including robust pulmonary infiltrates, increased capillary permeability, altered pulmonary physiology and inflammatory cytokine release 19, 20 Using this system, we demonstrate that the development of IPS is associated with increases in lung mRNA and bronchoalveolar lavage fluid (BALF) protein levels of RANTES that coincide with elevated pulmonary expression of CCR1 and CCR5.
Furthermore, our data specifically show that RANTES secreted by donor T cells contributes to IPS and that the use of RANTES deficient T cells results in a significant reduction in lung injury after allogeneic SCT regardless of the phenotype of the co-administered bone marrow cells. Mice were transplanted according to a standard protocol as previously described 37 . Briefly, B6D2F1 mice received cell mixtures of 5 x 10 6 bone marrow (BM) cells supplemented with 1.8 -2.0 x 10 6 splenic T cells from either syngeneic (B6D2F1) or allogeneic C57BL/6, B6 Ly5.2 or B6 RANTES-/-donors. T cell purification was performed by magnetic-bead-separation using CD4 and CD8 MicroBeads and the autoMACS system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's protocol with > 85% of cells obtained being positive for CD4 or CD8 surface antigens (data not shown). Percentages of purified CD4+ and CD8+ T cells did not significantly differ between donors. Prior to transplant, host mice received 11 or 13 Gy of TBI ( 137 Cs source) delivered in two fractions separated by three hours to reduce gastrointestinal toxicity. Mice were subsequently housed in sterilized micro-isolator cages and received normal chow and autoclaved hyperchlorinated water for the first three weeks post SCT and filtered water thereafter. conjugated MoAbs to CD4, CD8 for flow cytometric analysis as previously described 10 . All
MATERIALS AND METHODS

Mice and stem cell transplantation
MoAbs were purchased from BD Biosciences Pharmingen (San Diego, CA).
Monocyte/macrophage counts were determined by subtracting the sum counts of CD4+, CD8+
and GR-1+ cells from the total BALF counts. B220+ B lymphocytes represent only 1% of total cells after syngeneic or allogeneic SCT and were not separately differentiated (data not shown).
Intracellular cytokine analysis
For intracellular RANTES staining, BAL cells were stimulated with the Leukocyte Activation Cocktail in the presence of GolgiPlug™ (BD Biosciences Pharmingen, San Diego, CA) for four hours and then stained using reagents from the Intracellular Cytokine Staining Kit (BD Biosciences Pharmingen, San Diego, CA) according to the manufacturer's protocol. RANTES staining was performed using either unlabelled rabbit anti-RANTES (mouse) Abs (Serotec Inc., Raleigh, NC) or rabbit isotype IgG control Abs as primary antibodies and subsequent detection using FITC conjugated goat-anti-rabbit IgG secondary antibody (Zymed Laboratories Inc, San Francisco, CA). Three-color flow cytometric analysis of 1x10 4 
Semiquantitative histopathology of lung, liver and intestine
Pulmonary toxicity after SCT was determined by examination of lung histopathology in transplanted animals 42 days after transplant as previously described 38 . Hematoxylin-eosin stained lung sections from individual mice were coded without reference to mouse type or prior treatment regimen and independently examined by C.L. to establish an index of injury. Lung tissue was evaluated for the presence of periluminal infiltrates (around airways and vessels) or parenchymal pneumonitis (involving the alveoli or interstitium) using a previously described semi-quantitative scoring system that incorporates both the severity (periluminal infiltrates: 0 = no infiltrates, 1 = 1-3 cell diameters thick, 2 = 4 -10 cell diameters thick, 3 = >10 cell diameters thick; pneumonitis: 0 = no infiltrates, 1 = increased cells only visible at high magnification (x400), 2 = easily seen cellular infiltrate or interstitial thickening, 3 = consolidation by inflammatory cells and interstitial thickening) and extent (percentage of lung tissue involved: 5%-25% = 1, >25%-50% = 2, >50% = 3) of histopathology 38 .
Detailed gastrointestinal (GI) tract and liver histopathologic analysis was performed in a blinded fashion by C.L. 42 days after transplant as previously described [39] [40] [41] . Specifically, seven parameters each were scored for small bowel (villous blunting, crypt regeneration, crypt epithelial cell apoptosis, crypt loss, luminal sloughing of cellular debris, lamina propria inflammatory cell infiltrate, and mucosal ulceration), large bowel (crypt regeneration, crypt epithelial cell apoptosis, crypt loss, surface colonocyte vacuolization, surface colonocyte attenuation, lamina propria inflammatory cell infiltrate, and mucosal ulceration), and ten 
Clinical GVHD and survival
Survival was monitored daily, and GVHD clinical scores were assessed weekly by a scoring system incorporating five clinical parameters: weight loss, posture (hunching), mobility, fur texture, and skin integrity, as previously described 38 .
RNase Protection Assay (RPA)
Determination of mRNA expression by the RNase protection assay was completed as previously described using the multiprobe-template sets mCK-5b and mCR-5 purchased from BD Biosciences Pharmingen (San Diego, CA) 
Measurement of cytokine and chemokine protein levels by ELISA
Concentrations of RANTES were measured in BAL fluid and serum using an ELISA kit (R&D Systems, Minneapolis, MN). Assays were performed according to the manufacturer's protocol. ELISA plates were read by microplate reader (Bio-Rad Laboratories, Hercules, CA).
Immuno-neutralization of RANTES
Polyclonal Abs against RANTES were generated in multiple-site immunized New Zealand White rabbits using the peptide sequence NH2-GCAYLSLELPRAHVKEYFYT-OH for RANTES (BioSynthesis Inc., Lewisville, TX). The specificity of the anti-RANTES antibodies was rigorously screened before its use in SCT experiments, and it lacked cross-reactivity with other chemokines For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From of Transwell inserts (6.5 mm diameter; 5-µm pore size) (Corning Costar, Corning, NY). Inserts were placed in the corresponding lower wells containing control serum alone (basal), control serum plus chemokine (positive control) or polyclonal Abs to RANTES plus chemokine (experimental group). After four hours of migration at 37° Celsius, inserts were removed and the sera in the lower chambers were collected. The wells were then thoroughly washed with 1 ml of media (x 5) and aliquots were combined with the first collection sample. The numbers of cells that migrated to the lower chamber were determined by using a Z1 Coulter Counter (Beckman Coulter Inc., Fullerton, CA). The percentage of cells that migrated from the upper into the lower chamber was calculated and ultimately averaged from triplicate wells.
Statistical considerations
All values are expressed as the mean ± standard error of the mean (SEM). Statistical comparisons between groups were completed using the parametric independent sample t-test if n>5 animals per group and using the Mann-Whitney test if n<5 animals per group. The Wilcoxon rank-test was used for analyzing survival data.
only.
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RESULTS
Enhanced pulmonary expression of RANTES correlates with the initial influx of donor T cells into the lungs after allogeneic SCT.
Lethally (1300 cGy split dose) irradiated B6D2F1 mice received SCT from either syngeneic (B6D2F1) or allogeneic (B6 CD45.1+) donors as described in Materials and Methods. RNA was isolated from the lungs of transplanted animals on days 2, 7, 14, 28 and 42 after transplant and mRNA levels for RANTES were determined by RNase protection assay. RANTES mRNA expression was low two days after allo-SCT and indistinguishable from syngeneic controls (Figure 1a ) whereas RANTES protein expression was not detectable in either group (data not shown). BALF cellularity was also low in both groups at this time, and donor derived T cells
were not yet detectable in allo-SCT recipients (Figure 1a) . By contrast, mRNA levels of RANTES were significantly increased in allo-SCT recipients by day 7, remained elevated compared to syngeneic controls at all subsequent time points and correlated with elevated levels of RANTES protein in the BALF on days 14 (277.7 ± 21.2 vs. 18.2 ± 18.2 pg/ml) and 42 (103.3 ± 40.1 vs. 0.8 ± 0.8 pg/ml) (figure 1b). Of particular note, the initial increase in RANTES mRNA expression seen after allo-SCT correlated with the influx of donor derived T cells into the lungs of these animals as early as day 7 (98% CD8+ and 94% CD4+ % donor versus 2% CD8+ and 6% CD4+ host) through day 14 (figure 1c). As noted above, CCR5 and CCR1 are the primary receptors for RANTES and can be expressed on a variety of effector cells, including macrophages, that have been shown to contribute to experimental IPS 10, 19 . RNA was isolated from the lungs of transplanted animals on days 7, 14, 28 and 42, and CCR5 and CCR1 expression was determined by RNase protection assay.
Increases in pulmonary RANTES mRNA levels after allo-SCT were associated with the elevated expression of CCR5 and CCR1 mRNA in the lungs of these animals compared to syngeneic controls (figure 2a-c). Changes in chemokine receptor expression coincided with the influx of donor derived macrophages into the lung; flow cytometry using antibodies to CD45.1 (donor marker) and CD45.2 (host marker) and forward-side scatter characteristics for pulmonary macrophages revealed that only 10% of macrophages were of donor origin on day 7, and turnover was not complete until four weeks after SCT (figure 2d). Similar finding were noted when BALF cells were co-stained with antibodies to the cell surface marker F4/80 and either CD45.1 or CD45.2 (data not shown). Moreover, the enhanced expression of both CCR5 and CCR1 ultimately reflected increases in inflammatory cell infiltration into both the broncho-alveolar space and the lung parenchyma of allo-SCT recipients consistent with the evolution of lung injury observed in this experimental model (table 1) RNA was isolated from the lungs of transplanted animals on days 7, 14, 28 and 42, and CCR5 and CCR1 expression was determined by RNase protection assay as described in figure 1. (A-C) Pulmonary CCR5 and CCR1 mRNA expression were significantly increased after allo-SCT at all time points when compared to syngeneic controls. On days 7, 14 and 28, monocyte/macrophage chimerism was determined in the BALF of transplanted mice by flow cytometry using antibodies to CD45.1 (donor marker) and CD45.2 (host marker) and either forward-side scatter Since RANTES can be secreted both by hematopoietic 32, 33 and non-hematopoietic [26] [27] [28] [29] [30] [31] cells, donor-derived (hematopoietic) and host-derived (non-hematopoietic) cells may contribute to the increase in RANTES expression seen in the lung after allogeneic SCT. However, RPA data revealed that the initial rise in RANTES mRNA expression coincided with the arrival of donor T cells to the lung. Therefore, we hypothesized that donor-derived RANTES would contribute to the development of IPS. To test this hypothesis, B6D2F1 mice were again conditioned with 1300cGy and received SCT from either syngeneic (B6D2F1), allogeneic wild-type B6 or allogeneic RANTES deficient (RANTES-/-) B6 donors. Animals were analyzed at 4 and 6 weeks after SCT for lung histology along with BALF cellularity and cellular phenotypes. As shown in figure 3 , lungs harvested from syngeneic SCT recipients remained essentially normal, but recipients of allo-SCT from wild-type B6 donors developed significant lung histopathology that was characterized by a dense mononuclear infiltrate around both bronchial and vascular structures and interstitial inflammation (figure 3a). By contrast, allogeneic SCT from RANTES-/-donors resulted in a significant reduction of lung pathology and BALF cellularity at weeks 4 and 6 after SCT compared to wild-type controls ( figure 3a-c) . Specifically, the numbers of CD8+ T cells and monocytes/macrophages were significantly decreased ( figure 3e-f) ; whereas, numbers of CD4+ T cells and GR-1+ granulocytes were also reduced, but did not reach statistical significance. This protective effect was associated with improved overall survival (week 6: 83% vs. 54%) after allo-SCT, but GVHD-related scores for the liver and the large and small bowel were not significantly different between allogeneic groups (figure 4). Lethally irradiated B6D2F1 mice received SCT from either syngeneic B6D2F1 (b), or allogeneic B6 wild-type (c) or B6 RANTES-/-(c) donors as described in figure 3 . Transplanted animals were monitored daily for survival (A). At week six, histopathology of the liver (B) along with the small and large bowel (C) were assessed for GVHD severity using a semiquantitative scoring system specific for each tissue. Data are combined from two comparable experiments, n = 10-28 per group for survival data and n = 9-14 per group for pathology data; *p < 0.06 only.
In vivo neutralization of RANTES reduces the severity of IPS after allo-SCT.
The results using RANTES deficient mice as SCT donors were intriguing and suggested that RANTES specific immuno-neutralization strategies would also be effective in reducing the severity of IPS. We therefore generated polyclonal antibodies to RANTES using the peptide sequence NH2-GCAYLSLELPRAHVKEYFYT-OH. In our first set of experiments, we determined whether the antibodies we developed effectively inhibited T cell migration in vitro. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From experiments in this system, allo-SCT recipients receiving control serum developed significant lung injury; whereas, immuno-neutralization of RANTES resulted in a significant reduction in both lung pathology and BALF cellularity (Figure 5b ). The administration of rabbit serum had no effect on lung histopathology in syngeneic controls nor were symptoms of serum sickness observed (data not shown).
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RANTES production by donor T cells but not of bone marrow derived-accessory cells is critical to the development of lung injury after allogeneic SCT.
Data in figure 3 
DISCUSSION
The development of acute GVHD and IPS continue to limit the utility of allogeneic SCT, particularly when unrelated volunteers are used as stem cell donors. Risk factors for IPS consistently include conditioning with TBI, the presence of acute GVHD and advanced recipient age 3, 4, [42] [43] [44] [45] [46] . The association between GVHD and lung injury in both the acute and chronic settings suggests similar mechanisms of injury may be operative, but a causal relationship between the two disorders remains controversial. However, experimental and clinical studies do suggest that synergy between the intensity of SCT conditioning regimens and alloreactive T cell responses may significantly contribute to the deleterious outcome of IPS after allo-SCT 7, 8, 47 . The pathophysiology of IPS is complex, and both animal and human data support the involvement of inflammatory cytokines and cellular effectors in the evolution of this process [9] [10] [11] [12] [13] [14] [15] [16] [17] . Although alloreactive Th1/Tc1 lymphocytes and donor monocytes and macrophages have been shown to play a significant role in the evolution of lung injury after allo-SCT 12, 16, [19] [20] [21] 40 , the mechanisms responsible for leukocyte recruitment to the lung in this setting remain incompletely understood.
In this study, we used an established murine model of IPS to examine the contribution of the CC chemokine RANTES to lung histopathology observed following allo-SCT. Increased RANTES expression in the lung has been previously reported following allo-SCT [18] [19] [20] , but a mechanistic relationship between RANTES and IPS had not been established. We demonstrate that mRNA and protein levels of RANTES are increased in the lung after allo-SCT. Since the lymphoid and myeloid cell types contributing to IPS can secrete and respond to RANTES, we hypothesized that donor leukocytes may assist in regulating their own recruitment to the lung after transplant. We found that allo-SCT using RANTES deficient donor cells results in a significant reduction in the severity of IPS. Importantly, SCT studies wherein wild-type bone marrow cells were admixed with RANTES deficient T cells and visa versa revealed that RANTES production by donor T cells is particularly important to the subsequent recruitment of leukocytes to the lung after allo-SCT. This observation is supported by our data showing that donor T cells present in the lung by week 2 after allo-SCT actively produce RANTES and by other studies where RANTES production by CD8+ and/or CD4+ T cells directly contributed to the infiltration of cells and the loss of skin and cardiac allografts [48] [49] [50] [51] .
A role for chemokine receptor:ligand interactions involving RANTES has been implicated in several models of pulmonary inflammation and also, as alluded to above, in experimental and clinical allograft rejection 48, 49, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . In some of these studies, targeting of the biologic effects of RANTES in vivo by using either neutralizing antibodies or intrinsically inactive receptor antagonists resulted in reduced lymphocyte and macrophage infiltration to sites of inflammation 55, 56, [59] [60] [61] . Furthermore, specific over-expression of RANTES in the lungs of rats leads to infiltration of cells into the pulmonary parenchyma and bronchoalveolar space comparable to that seen after allogeneic SCT 62 . In the study reported herein, enhanced RANTES expression after allogeneic SCT was also associated with elevations in mRNA levels for CCR1 and CCR5. to the liver and the peyer's patches after allo-SCT in a non-myeloablative SCT setting 66, 67 . Of particular note, migration to the peyer's patches was directly related to the expression of RANTES at that tissue site 66, 67 . By contrast, the absence of CCR5-/-on donor cells has been recently shown to exacerbate mortality from GVHD under myeloablative conditions 68, 69 .
Our data reveal an important, but not exclusive, role for donor T cell-derived RANTES in the development of IPS. The residual lung histopathology observed after allo-SCT with RANTES deficient donor cells may be explained by several factors. RANTES is not solely produced by activated T cells, but can also be expressed by a variety of cell types including fibroblasts, epithelial and endothelial cells 24, [26] [27] [28] [29] [30] [31] 53 . Inflammatory cytokines, including TNFK, IFNM and IL-1, lead to significant upregulation of RANTES expression in non-hematopoietic cells [70] [71] [72] [73] , and This hypothesis would therefore suggest that novel strategies targeting the regulation of effector cell recruitment to the lung (or other GVHD target tissues) might serve as effective adjuncts to standard therapy intended to prevent or treat these serious complications of allo-SCT.
